Indeed, well-directed ROS-quenching antioxidants and neurotoxic metal chelation, anti-viral, anti-NF-kB, anti-miRNA-146a (antagomir) pharmacotherapeutic approaches, or any combinations of these may be of use in the clinical management of AD, PrD, and other related progressive and terminal neurodegenerative disease processes with an inflammatory component (15, 22, 22, 23, 54, 55, 57–62). This evidence concerns the gene PEPD and Alzheimer disease.